at 308

AT-308 is a bio-active chemical.

ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively).ERD-308 is a highly potent PROTAC degrade

KAG-308 is an effective selective and orally active agonist of the EP4 receptor (Ki: 2.57 nM and EC50: 17 nM for human EP4 receptor), more selective over EP1, EP2, EP3, and IP receptor. KAG-308 suppresses colitis and promotes histological mucosal healing,

RJS308 is a PROTAC degrader of cyclosporin A (cyclosporin A) with a DC50 of 284 nM. It exhibits antiviral activity by inhibiting the replication of HIV-1 and HCV. (Pink: ligand for target protein CypA ligand-2; Black: linker; Blue: ligand for E3 ligase VHL (S,R,S)-AHPC-Me)

308-R-C4-PEG3-C1-Boc is an SGK3 ligand-linker conjugate, utilized in the synthesis of PROTAC SGK3 degrader-2.

NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model. NRPa-308 is used in angiogenesis and tumor biology research systems to investigate neuropilin-1-mediated vascular signaling, endothelial cell proliferation regulation, and tumor microenvironment modulation in xenograft cancer models.

Antibacterialagent 308 (Compound A25) is an antibacterial agent that targets bacterial cell membranes by binding to phosphatidylethanolamine, disrupting membrane polarization, and increasing intracellular ROS levels. It exhibits significant antibiofilm activity against Staphylococcus aureus (S. aureus) and shows potent activity against methicillin-resistant Staphylococcus aureus (MRSA).

CRBN ligand-308 is an E3 ubiquitin ligase cereblon (CRBN) ligand utilized for the recruitment of cereblon proteins. It can be linked to a target protein ligand via a linker to form a PROTAC.

LGF308 is a PROTAC degrader targeting BRD4, exhibiting selective cytotoxicity against cancer cells compared to normal cells. It facilitates the formation of a ternary complex between BRD4 and DCAF11, leading to BRD4 degradation. LGF308 induces apoptosis in tumor cells by upregulating apoptosis-related proteins and inhibits proliferation and migration in breast cancer and triple-negative breast cancer cell lines. LGF308 is applicable for breast cancer research.

Anticanceragent 308 (compound 3s) is an AKT inhibitor with antitumor activity. It reduces the total AKT protein levels, thereby inhibiting the prosurvival PI3K/AKT signaling pathway. Anticanceragent 308 induces apoptosis, disrupts mitochondrial membrane potential, promotes the accumulation of reactive oxygen species (ROS) in mitochondria, and causes cell cycle arrest. It can also inhibit cancer cell migration and is applicable for research in breast cancer, lung adenocarcinoma, cervical cancer, prostate cancer, and hepatocellular carcinoma.

WB-308 is an EGFR inhibitor that acts by decreasing NSCLC cell proliferation and colony formation and causing G2/M arrest and apoptosis.

K 308 is a bioactive chemical.

PSAM (pharmacologically selective actuator module) agonist. Activates PSAML141F-GlyR chimeric ion channels. Inhibits activity of neurons expressing PSAML141F-GlyR in vivo and activates locus coeruleus noradrenergic neurons expressing PSAML141F,Y115F-5-HT3 ion channels. Recommended concentration for use in mice is 5 mg/kg or lower. Plasmid vectors for the transfection of cells with PSAML141F-GlyR and PSAML141F,Y115F-5-HT3 are available from Addgene. Lovett-Barron et al (2012) Regulation of neuronal input transformations by tunable dendritic inhibition. Nat.Neurosci. 15 423 PMID:22246433 |Satoh et al (2016) Context-dependent gait choice elicited by EphA4 mutation in Lbx1 spinal interneurons. Neuron 89 1046 PMID:26924434 |Atasoy et al (2012) Deconstruction of a neural circuit for hunger. Nature 488 172 PMID:22801496 |Hirschberg et al (2017) Functional dichotomy in spinal- vs prefrontal-projecting locus coeruleus modules splits descending noradrenergic analgesia from ascending aversion and anxiety in rats. Elife 6 e29808 PMID:29027903

LG308 shows antimicrotubule activity which is a novel synthetic compound. LG308 induces apoptosis, cell death, and significantly suppresses tumor growth that has the potential for the prostate cancer research. LG308 induces arrest of mitotic phase and significantly inhibits progression of G2/M which is associated with the upregulation of cyclin B1 and mitotic marker MPM-2 and the dephosphorylation of cdc2 [1].

LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.

QC-308 HCl is a novel Heme Oxygenase-1 Inhibitor (HO-1 IC50=0.27μM; HO-2 IC50=0.46μM).

HU-308, a synthetic cannabinoid analogue, is a highly selective agonist of the CB2 receptor. It demonstrates an affinity for the CB2 receptor that is over 440 times greater than its affinity for the CB1 receptor, which are predominantly found in immune cells. This compound plays a crucial role in modulating the immunosuppressive effects of the endocannabinoid system (ECS). Additionally, HU-308 possesses anti-inflammatory and neuroprotective properties, and it regulates the function of microglia. Its potential applications include research into neuroinflammation and retinal diseases.

ANT308 is an antagonist of the vasoactive intestinal peptide (VIP receptor). It significantly enhances T cell activation and proliferation. By inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin, ANT308 suppresses melanoma cell migration and metastasis while inducing apoptosis. This compound is useful for research in acute myeloid leukemia (AML) and uveal melanoma (UVM).

ANT308 TFA serves as an antagonist for the vasoactive intestinal peptide (VIP receptor). It significantly enhances the activation and proliferation of T cells. By inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin, ANT308 TFA impedes the migration and metastasis of melanoma cells and induces apoptosis. This compound is applicable in research related to acute myeloid leukemia (AML) and uveal melanoma (UVM).

CC260, a selective inhibitor for PI5P4Kα and PI5P4Kβ with Kis of 40 nM and 30 nM respectively, exhibits minimal to no inhibition against other protein kinases like Plk1 and RSK2. It is applicable in the research of cell energy metabolism, diabetes, and cancer[1].